The Future Of the Regenerative Medicine Market
The future of the regenerative medicine field is very bright! FDA commissioner Scott Gottlieb recently stated;
“We’re at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine,”
The BioStem team is dedicated to addressing all concerns brought up by both the FDA, and other reputable medical practitioners, by working in concert with the FDA and other regulatory authorities to define what the new standards moving forward that will normalize and properly regulate the industry. Our approach is to develop regenerative biologics, using proven clinical and pharmaceutical SOP’s and developmental processes.
Prognosticators predict that the global regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6% from 2016 to 2021. The major factor driving the growth of this market are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population.